180 related articles for article (PubMed ID: 34339834)
1. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.
Lopez-Santillan M; Lopez-Lopez E; Alvarez-Gonzalez P; Martinez G; Arzuaga-Mendez J; Ruiz-Diaz I; Guerra-Merino I; Gutierrez-Camino A; Martin-Guerrero I
Crit Rev Oncol Hematol; 2021 Sep; 165():103430. PubMed ID: 34339834
[TBL] [Abstract][Full Text] [Related]
2. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
3. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
4. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.
Khanmohammadi S; Fallahtafti P
J Cell Mol Med; 2023 Jul; 27(14):1928-1946. PubMed ID: 37246627
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
8. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
10. CD56-positive diffuse large B-cell lymphoma/leukemia with
Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H
J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958
[TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
[TBL] [Abstract][Full Text] [Related]
12. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
13. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma.
Özçalımlı A; Erdoğdu İH; Turgutkaya A; Yavaşoğlu İ; Döger FK; Bolaman AZ
Int J Lab Hematol; 2023 Jun; 45(3):310-316. PubMed ID: 36576110
[TBL] [Abstract][Full Text] [Related]
15. The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
Mellert K; Martin M; Lennerz JK; Lüdeke M; Staiger AM; Kreuz M; Löffler M; Schmitz N; Trümper L; Feller AC; Hartmann S; Hansmann ML; Klapper W; Stein H; Rosenwald A; Ott G; Ziepert M; Möller P
Br J Haematol; 2019 Dec; 187(5):627-637. PubMed ID: 31407320
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
17. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
18. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
19. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.
Harkins RA; Chang A; Patel SP; Lee MJ; Goldstein JS; Merdan S; Flowers CR; Koff JL
Expert Rev Hematol; 2019 Nov; 12(11):959-973. PubMed ID: 31513757
[No Abstract] [Full Text] [Related]
20. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs.
Ofori K; Bhagat G; Rai AJ
Br J Clin Pharmacol; 2021 Feb; 87(2):284-294. PubMed ID: 33080045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
